Town and district hub in western Uganda, site of Bundibugyo District’s headquarters
A Bundibugyo Ebola outbreak is driving rapid development of vaccines and antibody therapies. Doses of MBP134 are being used for compassionate use and clinical trials, while several vaccine candidates are advancing toward human testing. Trials face challenges from battlefield-like conditions in eastern Congo and Uganda.
Health authorities have reported at least 1,759 confirmed Ebola cases and about 600 deaths in the Democratic Republic of Congo since mid-May, driven by the rare Bundibugyo strain. The World Health Organization has enrolled the first patient in a trial testing MBP134 and remdesivir; treatment centres are strained and insecurity and funding shortfalls are hindering response.
The Bundibugyo-strain Ebola outbreak in the DR Congo has intensified, with cases rising and deaths increasing. Health workers are striking over unpaid salaries, while international partners warn the official figures may undercount the true toll. Trials for treatments have begun, and vaccination efforts remain limited by the absence of a vaccine for this strain.
A UK-Oxford vaccine candidate has begun Phase I testing in healthy volunteers to assess safety and immune response. The work leverages the same technology as the Oxford–AstraZeneca Covid jab. Trials are planned in Africa with regional partners as the outbreak continues in the Democratic Republic of Congo.
Two articles report on the Congo’s Ebola response amid ongoing unrest. Health workers warn that strikes and mob attacks are complicating response efforts as the outbreak continues to expand, with thousands of cases and hundreds of deaths across Ituri province.
Uganda and Africa CDC have formally urged the United States to remove travel restrictions tied to the Ebola outbreak. Uganda reports no new cases since July 16, with the last patient discharged, while the DRC faces a worsening Bundibugyo outbreak. Regional partners warn that border controls complicate trade and health work, as WHO warns the outbreak could be larger than detected.
The Bundibugyo-strain Ebola outbreak in the Democratic Republic of the Congo has reached over 4,000 confirmed cases with about 1,900 deaths, and is progressing at an unprecedented rate. Health workers face unpaid wages, security threats and misinformation while WHO and Africa CDC coordinate trials and vaccination efforts amid a volatile security situation.
The Democratic Republic of Congo’s Bundibugyo-variant Ebola outbreak has reached 4,945 confirmed cases and at least 2,325 deaths. The outbreak, the largest in the country’s history, is expanding rapidly with many cases detected late, and care access remains severely limited. Global health authorities are evaluating experimental options while vaccines and treatments remain limited.
The DRC has recorded the largest-ever Bundibugyo Ebola outbreak, with more than 5,600 confirmed cases and over 2,700 deaths, and international agencies are racing to respond. WHO and partners have allocated 70,000 Ervebo doses—20,000 for a Phase III trial and 50,000 for frontline workers—while CEPI has awarded up to $16.5m to advance a Minapharm Bundibugyo vaccine into early human trials. Uganda has received MBP134 antibody vials as a precautionary measure.
Since mid‑May the Democratic Republic of Congo has recorded more than 5,600 Ebola cases and about 2,700 deaths; the outbreak has spread across six provinces and is covering an area larger than France. The UN and aid groups have warned infections are rising faster than the international response, funding is running short and frontline workers face attacks and heavy losses.
The Democratic Republic of the Congo faces the largest Ebola outbreak on record, with thousands of confirmed cases and deaths. Trust deficits and misinformation challenge responders, but community-led efforts are driving tracing, care, and safe burials. Frontline workers report stress and delayed pay, while aid demands rise as the outbreak accelerates.
The Bundibugyo strain of Ebola is spreading across eastern Congo, with thousands of cases and deaths reported. Health workers are receiving Ervebo under compassionate-use rules as vaccination campaigns expand amid ongoing insecurity and displacement. WHO warns the outbreak remains out of control while vaccines are being tested for effectiveness against Bundibugyo.